Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

The many roles of histone deacetylases in development and physiology: implications for disease and therapy.

Haberland M, Montgomery RL, Olson EN.

Nat Rev Genet. 2009 Jan;10(1):32-42. doi: 10.1038/nrg2485. Review.

2.

HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics.

Gallinari P, Di Marco S, Jones P, Pallaoro M, Steink├╝hler C.

Cell Res. 2007 Mar;17(3):195-211. Review.

3.

Histone deacetylases: target enzymes for cancer therapy.

Mottet D, Castronovo V.

Clin Exp Metastasis. 2008;25(2):183-9. Epub 2007 Dec 5. Review.

PMID:
18058245
4.

The role of histone deacetylases (HDACs) in human cancer.

Ropero S, Esteller M.

Mol Oncol. 2007 Jun;1(1):19-25. doi: 10.1016/j.molonc.2007.01.001. Epub 2007 Mar 7. Review.

5.

Protein deacetylases: enzymes with functional diversity as novel therapeutic targets.

Yoshida M, Shimazu T, Matsuyama A.

Prog Cell Cycle Res. 2003;5:269-78. Review.

PMID:
14593721
6.

Erasers of histone acetylation: the histone deacetylase enzymes.

Seto E, Yoshida M.

Cold Spring Harb Perspect Biol. 2014 Apr 1;6(4):a018713. doi: 10.1101/cshperspect.a018713. Review.

PMID:
24691964
7.

Histone deacetylases in kidney development: implications for disease and therapy.

Chen S, El-Dahr SS.

Pediatr Nephrol. 2013 May;28(5):689-98. doi: 10.1007/s00467-012-2223-8. Epub 2012 Jun 22. Review.

PMID:
22722820
8.

Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications.

Li Z, Zhu WG.

Int J Biol Sci. 2014 Jul 2;10(7):757-70. doi: 10.7150/ijbs.9067. eCollection 2014. Review.

9.

Histone deacetylase inhibitors: a novel class of therapeutic agents in diabetic nephropathy.

Lee HB, Noh H, Seo JY, Yu MR, Ha H.

Kidney Int Suppl. 2007 Aug;(106):S61-6. Review.

PMID:
17653213
10.

Histone deacetylases and cancer: causes and therapies.

Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK.

Nat Rev Cancer. 2001 Dec;1(3):194-202. Review.

PMID:
11902574
11.

Histone tail modifications and noncanonical functions of histones: perspectives in cancer epigenetics.

Hadnagy A, Beaulieu R, Balicki D.

Mol Cancer Ther. 2008 Apr;7(4):740-8. doi: 10.1158/1535-7163.MCT-07-2284. Review.

12.

Histone deacetylases and mechanisms of regulation of gene expression.

Chen HP, Zhao YT, Zhao TC.

Crit Rev Oncog. 2015;20(1-2):35-47. Review.

PMID:
25746103
13.

From discovery to the coming generation of histone deacetylase inhibitors.

Yoshida M, Matsuyama A, Komatsu Y, Nishino N.

Curr Med Chem. 2003 Nov;10(22):2351-8. Review.

PMID:
14529478
14.

Focus on acetylation: the role of histone deacetylase inhibitors in cancer therapy and beyond.

Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG.

Expert Opin Investig Drugs. 2007 May;16(5):569-71. Review.

PMID:
17461732
15.

Histone deacetylases and their functions in plants.

Ma X, Lv S, Zhang C, Yang C.

Plant Cell Rep. 2013 Apr;32(4):465-78. doi: 10.1007/s00299-013-1393-6. Epub 2013 Feb 14. Review.

PMID:
23408190
16.

Therapeutic potential for HDAC inhibitors in the heart.

McKinsey TA.

Annu Rev Pharmacol Toxicol. 2012;52:303-19. doi: 10.1146/annurev-pharmtox-010611-134712. Epub 2011 Sep 26. Review.

PMID:
21942627
17.

Histone deacetylases and cancer.

Barneda-Zahonero B, Parra M.

Mol Oncol. 2012 Dec;6(6):579-89. doi: 10.1016/j.molonc.2012.07.003. Epub 2012 Aug 27. Review.

18.

Isoform-selective histone deacetylase inhibitors.

Itoh Y, Suzuki T, Miyata N.

Curr Pharm Des. 2008;14(6):529-44. Review.

PMID:
18336298
19.

HDACi--going through the mechanisms.

Wanczyk M, Roszczenko K, Marcinkiewicz K, Bojarczuk K, Kowara M, Winiarska M.

Front Biosci (Landmark Ed). 2011 Jan 1;16:340-59. Review.

PMID:
21196174
20.

HDAC inhibitors for the treatment of cancer.

Secrist JP, Zhou X, Richon VM.

Curr Opin Investig Drugs. 2003 Dec;4(12):1422-7. Review.

PMID:
14763127
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk